Amy Adelberger,
Founder and CEO,
Global Impact Advisors
Amy founded and leads Global Impact Advisors, a boutique strategy and evaluation advisory firm, where she is responsible for all aspects of the business including strategic direction, client engagement, and project delivery. She advises foundations, non-profits, and universities on achieving their program outcomes and enhancing their impact.
Her experience includes development of strategic plans, including setting organization, portfolio, and program level direction, as well as assessing progress through a variety of methods. She regularly leads multi-disciplinary teams that conduct stakeholder analyses, capabilities assessments, and process evaluations. She also engages with a range of funders in global health, including both private foundations and public sector donors.
Prior to founding GIA, Amy was a Program Officer in Global Health at the Bill & Melinda Gates Foundation. She managed an end-to-end program strategy, which included a focus on discovery, development, and delivery of Tuberculosis drugs, diagnostics, and vaccines. Amy received a BA in History from Brown University and an MPH from the University of Washington.
Impact and Return: The Potential Value of Developing Country Markets
Wednesday, 4 October 2017 at 14:00
Add to Calendar ▼2017-10-04 14:00:002017-10-04 15:00:00Europe/LondonImpact and Return: The Potential Value of Developing Country MarketsPOC Diagnostics, Global Health-Viral Diseases 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Developing country markets in low and lower middle income countries continue to face high rates of both communicable and non-communicable diseases. As incomes rise, the ratio of communicable to non-communicable disease lowers. However, as populations grow, and grow quickly, both communicable and non-communicable diseases remain a threat to the development of the poorest countries and their ability to achieve social and economic development goals. In the last 50 years, the world’s population has more than doubled. While global population growth rate is expected to slow, certain regions of the world, such as Africa, still have some of the highest population growth rates. This population growth, in conjunction with high disease burdens and low income status, creates an opportunity to develop the necessary tools and approaches to address the world’s most pressing global health problems. However, solutions to these problems cannot simply be developed in the first world and transported to the developing world. Entrepreneurs, industry, and academics must take into consideration the market and the ecosystem for which they are developing the product and focus on an end-to-end solution that envisions faster, better, and less expensive diagnosis and prompt treatment for all. Barriers do exist to accessing the lower income markets, but they are not insurmountable. Amy will discuss the opportunities for and the barriers to developing diagnostics for a global health market. She will provide practical advice on how to approach development of a diagnostic for the global health market, including focusing on funding and partnerships.
Add to Calendar ▼2017-10-02 00:00:002017-10-04 00:00:00Europe/LondonPOC Diagnostics, Global Health-Viral Diseases 2017POC Diagnostics, Global Health-Viral Diseases 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-10-04 14:00:002017-10-04 15:00:00Europe/LondonImpact and Return: The Potential Value of Developing Country MarketsPOC Diagnostics, Global Health-Viral Diseases 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
